The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549
FORM D

# OMB APPROVAL OMB Number: 3235-0076 Estimated average burden

hours per response: 4.00

## **Notice of Exempt Offering of Securities**

1. Issuer's Identity			
	Previous		
CIK (Filer ID Number)	Names	None	Entity Type
0001740279	Incysus Ther	apeutics, Inc.	Corporation
Name of Issuer			Limited Partnership
IN8BIO, INC.			Limited Liability Company
Jurisdiction of Incorporation/Or	ganization		General Partnership
DELAWARE			Business Trust
Year of Incorporation/Organiza	tion		Other (Specify)
Over Five Years Ago Within Last Five Years (Sp Yet to Be Formed	pecify Year)		
	a and Cantact Information		
2. Principal Place of Business	s and Contact Information		
Name of Issuer			
IN8BIO, INC.			
Street Address 1		Street Address 2	
EMPIRE STATE BUILDING		350 5TH AVENUE,	SUITE 5330
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
NEW YORK	NEW YORK	10118	(646) 600-6438
3. Related Persons			
Last Name	First Name		Middle Name
Но	William		
Street Address 1	Street Address 2		
c/o IN8bio, Inc.	Empire State Build	350 5th Ave Ste 5330	
City	State/Province/Co	ountry	ZIP/PostalCode
New York	NEW YORK		10118
Relationship: Executive O	fficer 🚺 Director 🔲 Promo	ter	
Clarification of Response (if Ne	cessary):		
Last Name	First Name		Middle Name
McCall	Patrick		
Street Address 1	Street Address 2		
c/o IN8bio, Inc.	Empire State Build	350 5th Ave Ste 5330	
City	State/Province/Co		ZIP/PostalCode
New York	NEW YORK	•	10118
Relationship: Executive O	fficer Director Promo	ter	
Clarification of Response (if Ne	cessary):		
Last Name	First Name		Middle Name
Roemer	Alan		S.
Street Address 1	Street Address 2		<del></del>
c/o IN8bio, Inc.		350 5th Ave Ste 5330	
City	State/Province/Co		ZIP/PostalCode
New York	NEW YORK		10118
Relationship: Executive O		ter	
Clarification of Response (if Ne	cessary):		

Last Name	First Name	Middle Name	
Brandt	Peter		
Street Address 1	Street Address 2		
c/o IN8bio, Inc.	Empire State Build 350 5th Ave Ste 5330		
City	State/Province/Country	ZIP/PostalCode	
New York	NEW YORK	10118	
Relationship: Executive O	rfficer 📝 Director 🦳 Promoter		
Clarification of Response (if Ne	ecessary):		
Last Name	First Name	Middle Name	
Fairbairn	Emily	R.	
Street Address 1	Street Address 2	K.	
c/o IN8bio, Inc.	Empire State Build 350 5th Ave Ste 5330		
		ZID/DestalCede	
City	State/Province/Country	ZIP/PostalCode	
New York  Relationship: Fxecutive O	NEW YORK  officer Director Promoter	10118	
Clarification of Response (if Ne	ecessary):		
Last Name	First Name	Middle Name	
Graff	Jeremy		
Street Address 1	Street Address 2		
c/o IN8bio, Inc.	Empire State Build 350 5th Ave Ste 5330		
City	State/Province/Country	ZIP/PostalCode	
New York NEW YORK		10118	
Relationship: Executive O	fficer 🕡 Director 🦳 Promoter		
Clarification of Response (if Ne	ecessary):		
Last Name	First Name	Middle Name	
Greenwood	Luba		
Street Address 1	Street Address 2		
c/o IN8bio, Inc.	Empire State Build 350 5th Ave Ste 5330		
City	State/Province/Country	ZIP/PostalCode	
New York	NEW YORK	10118	
Relationship: Executive O	officer Director Promoter		
Clarification of Response (if Ne	ecessary):		
Last Name	First Name	Middle Name	
Whitfill	Travis		
Street Address 1	Street Address 2		
c/o IN8bio, Inc.	Empire State Build 350 5th Ave Ste 5330		
City	State/Province/Country	ZIP/PostalCode	
New York	NEW YORK	10118	
	fficer Director Dromoter		
Clarification of Response (if Ne	ecessary):		
Last Name	First Name	Middle Name	
Epperly	Corinne		
Street Address 1	Street Address 2		
c/o IN8bio, Inc.	Empire State Build 350 5th Ave Ste 5330		
City	State/Province/Country	ZIP/PostalCode	
New York	NEW YORK	10118	
	officer Director Promoter		
Clarification of Response (if Ne	<u> </u>		
Last Name	First Name	Middle Name	
Lamb	Lawrence	MIGUIC NAITIC	
Street Address 1	Street Address 2		
Oli 661 Muul 699	JUGGU AUUUG33 Z		

c/o IN8bio, Inc.	Empire State Build 350 5th Ave Ste 5330	
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10118
Relationship:  Executive Officer D	irector 🔲 Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Rochlin	Kate	
Street Address 1	Street Address 2	
c/o IN8bio, Inc.	Empire State Build 350 5th Ave Ste 5330	
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10118
Relationship: Executive Officer D	irector 🔲 Promoter	
Clarification of Response (if Necessary):		
4. Industry Group		
Agriculture	Health Care	
Banking & Financial Services		Retailing
Commercial Banking	Biotechnology	Restaurants
Insurance	Health Insurance	Technology
Investing	Hospitals & Physicians	Computers
Investment Banking	Pharmaceuticals	Telecommunications
Pooled Investment Fund	Other Health Care	Other Technology
Is the issuer registered as	Manufacturing	Travel
an investment company under	Real Estate	Airlines & Airports
the Investment Company Act of 1940?	Commercial	
Yes No		Lodging & Conventions
Other Banking & Financial Service	Construction	Tourism & Travel Services
Business Services	REITS & Finance	Other Travel
Energy	Residential	Other
Coal Mining	Other Real Estate	
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		
5. Issuer Size		
Revenue Range OR	Aggregate Net Asset Value Ra	_
No Revenues  \$1 - \$1,000,000	No Aggregate Net Asset \	value
\$1,000,001 - \$5,000,000	\$5,000,000	
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,00	
\$25,000,001 -		
\$100,000,000	\$50,000,001 - \$100,000,0	000
Over \$100,000,000	Over \$100,000,000	
▼ Decline to Disclose	Decline to Disclose	
Not Applicable	Not Applicable	
6. Federal Exemption(s) and Exclusion(s	s) Claimed (select all that apply)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Investment Company A	ct Section 3(c)
Rule 504 (b)(1)(i)	Section 3(c)(1)	Section 3(c)(9)
Rule 504 (b)(1)(ii)		
Rule 504 (b)(1)(iii)	Section 3(c)(2)	Section 3(c)(10)
Rule 506(b)	Section 3(c)(3)	Section 3(c)(11)
Rule 506(c) Securities Act Section 4(a)(5)	Section 3(c)(4)	Section 3(c)(12)
0000111103 Act 00011011 4(a)(0)	Section 3(c)(5)	Section 3(c)(13)

	on 3(c)(6) [ ] Section 3(c)(14) on 3(c)(7)	
7. Type of Filing		
New Notice Date of First Sale 2024-10-04 First Sale Y  Amendment	et to Occur	
8. Duration of Offering		
Does the Issuer intend this offering to last more than one year?	Yes No	
9. Type(s) of Securities Offered (select all that apply)		
Equity Debt Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Right to Acquire Security	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities r Other Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combin merger, acquisition or exchange offer?  Clarification of Response (if Necessary):	nation transaction, such as a Yes V No	
11. Minimum Investment		
Minimum investment accepted from any outside investor \$0 USE	)	
12. Sales Compensation		
Recipient	Recipient CRD Number None	
Newbridge Securities Corporation	104065	
(Associated) Broker or Dealer None	(Associated) Broker or Dealer CRD Number None	
None	None	
Street Address 1	Street Address 2	
1200 North Federal Highway, Suite 400		
City	State/Province/Country	ZIP/Postal Code
Boca Raton	FLORIDA	33432
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US	
13. Offering and Sales Amounts		
Total Offering Amount \$12,379,983 USD or Indefinite		
Total Amount Sold \$12,379,983 USD		
Total Remaining to be Sold \$0 USD or Indefinite		
Clarification of Response (if Necessary):		
14. Investors		
Select if securities in the offering have been or may be sold enter the number of such non-accredited investors who already		
Regardless of whether securities in the offering have been investors, enter the total number of investors who already h	or may be sold to persons who do not qualify as accredited have invested in the offering:	73
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finder an estimate and check the box next to the amount.	s fees expenses, if any. If the amount of an expenditure is no	t known, provide
Sales Commissions \$742,799 USD Estimate		
Finders' Fees \$0 USD  Estimate		

Clarification of Response (if Necessary):

This does not include \$65,000 of out of pocket expenses that the Issuer reimbursed Newbridge Securities Corporation.

#### 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

Clarification of Response (if Necessary):

### Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### **Terms of Submission**

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
IN8BIO, INC.	/s/ Patrick McCall	Patrick McCall	Chief Financial Officer	2024-10-15

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

<sup>\*</sup> This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.